Researchers & R&D Institutions
Most innovation goes on outside Evolva.
This simple fact means we collaborate with a wide number of researchers and research organisations to widen our capabilities and access technologies that complement our own. We in-license technologies on a regular basis.
If you work on something that you think might be of interest to us, please get in touch.
As a partial guide to what we are interested in, we describe below, and provide links to, seven research consortia of which we are a member. Other information can be found under the “Who we are“, “Products” and “Science” tabs on this site.
CHASSY – Runs from 2016 to 2020
The aim of CHASSY is to deliver a suite of yeast strains that can serve as versatile platforms for the production of high value oleochemicals and aromatic molecules. In this consortium we are heading at integrating the knowledge gained from systems biology with the engineering tools of biology to redesign metabolic pathways in the target yeast species. These redesigned strains then have optimised levels of product precursors and serve as versatile chassis for the biotech industry. Learn more in the short explainer video.
Tet4Biotech – Runs from 2015-2018
Tet4Biotech aims to improve the production of ingredients in yeast using transporter technologies (transporters are proteins that pump out ingredients out of the yeast, or move an ingredient from one location in the yeast to another). Enabling ingredients to be secreted from yeast enables simpler purification processes and potentially increases yield.
The project includes the development and screening of a large transporter library to identify exporters of six high-value ingredients and the introduction of these exporters into yeast. It is a three year collaboration between DynaMo Center and Evolva, supported by a 6 million Danish krone grant from Innovation Fund Denmark.
Plant power – Runs from 2013-2018
Plant Power investigates the light-driven biosynthesis of complex terpenoids using cytochrome P450s. The project’s goal is to develop novel, carbon-neutral production platforms for complex terpenoids, create a general system for the production of other terpenoids, and establish state-of-the-art photo-bioreactor technology in Denmark.
Terpenoids are complex plant compounds with a wide range of valuable properties – for instance as anti-cancer agents, hormonal regulators or antibacterial agents. However they are difficult or impossible to synthesise chemically and are produced in plants only in minute amounts. The project transfers terpenoid biosynthetic pathways from higher plants to cyanobacteria and moss, and then couples them directly to the photosynthetic system in the chloroplasts – allowing light-driven production.
Other than Evolva participants include groups from the University of Copenhagen, the University of California, Berkeley, and the University of Kent. The project is funded by the Danish Council for Strategic Research. The total budget amounts to DKK 20.7m (CHF 3.5m).
PROMYS – Runs from 2013-2017
Promys’ goal is to implement a platform technology termed ligand responsive regulation and selection systems. This technology will be applied to deliver increased fermentation yields by continuously selecting for high yielding strains within a fermentation population.
Evolva’s role in the project is to construct a yeast that is able to produce high yields of a taste modulating ingredient. The biosynthetic pathway to this ingredient will be used in other parts of the project. PROMYS has total funding of EUR 7.2 million (CHF 8.9 million) from the European Union. It is part of the European Commission’s 7th Framework Programme for Research.
Yeastcell – Runs from 2013-2017
Yeastcell is an innovative research training programme for early stage researchers in yeast biotech. Since the time of Louis Pasteur and Christian Hansen, yeast has been central to biotechnology. The importance of training researchers for this area has been highlighted by multiple reports demonstrating the economic value of yeast biotechnology for Europe.
Evolva is one of 13 participants from 8 different European countries. The project is funded by the EU Initial Training Networks (ITN).
Chem21 – Runs from 2012-2017
CHEM 21 develops novel catalytic technologies for chemical and biochemical synthesis. The project focuses on base-metal catalysis, biocatalysis, synthetic biology and continuous flow processing and provides a research hub for European efforts in this area. It also acts as a source of the latest information on green chemistry metrics and develops training packages to embed the principles of sustainable manufacture in the education of future
Within CHEM21 Evolva works on the generation of various toolboxes for pathway expression in yeast as well as assembly of selected pathways in yeast. CHEM 21 brings together six pharmaceutical companies, five SMEs and eight universities from across Europe. The project is funded by the Innovative Medicines Initiative and has a total budget of EUR 26 million.
Bachberry – Ran from 2013-2016
BACHBERRY developed a series of methods to mine the untapped metabolic diversity of berries (blueberries, blackberries etc.). The functional benefits of various berry ingredients have been demonstrated in many recent studies on chronic diseases. In addition the ingredients can be used as cosmetics, flavours, natural colourants etc.
Unfortunately berry ingredients are often only present in small quantities, and are also difficult to purify. And their production in plants is influenced by environmental conditions and other non- controllable factors.
Bachberry generated knowledge that now allows the production of berry ingredients by brewing. It was funded with EUR 9.5m.
DIABAT – Ran from 2011-2015
Evolva was a member of a group of European companies and academic institutions, researching the role of brown adipose tissue (BAT) in the prevention and treatment of obesity and type 2 diabetes. Type 2 diabetes and its associated cardio-vascular complications have emerged as the leading causes of death in Western countries, associated with estimated health care costs of more than 30 billion Euros in the European Union per year.
DIABAT project was part-funded by the European Commission within the FP-7 programme.